Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price shot up 6.4% on Wednesday . The company traded as high as $12.07 and last traded at $12.17. 66,165 shares were traded during mid-day trading, a decline of 92% from the average session volume of 864,305 shares. The stock had previously closed at $11.44.
Wall Street Analyst Weigh In
A number of research firms have weighed in on REPL. HC Wainwright raised their price target on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. BMO Capital Markets raised their price target on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Finally, Jefferies Financial Group raised their price target on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $19.43.
Read Our Latest Research Report on REPL
Replimune Group Price Performance
The stock has a 50-day moving average price of $12.66 and a 200 day moving average price of $12.10. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm has a market cap of $897.22 million, a price-to-earnings ratio of -3.79 and a beta of 1.30.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, equities research analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CEO Sushil Patel sold 10,000 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares of the company's stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.80% of the company's stock.
Hedge Funds Weigh In On Replimune Group
A number of hedge funds and other institutional investors have recently made changes to their positions in REPL. Baker BROS. Advisors LP boosted its holdings in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Replimune Group by 11.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after purchasing an additional 1,083,633 shares in the last quarter. Redmile Group LLC boosted its holdings in Replimune Group by 2.6% in the 4th quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after purchasing an additional 124,344 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Replimune Group by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock valued at $43,546,000 after purchasing an additional 129,601 shares in the last quarter. Finally, Braidwell LP boosted its holdings in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
